Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma

被引:7
|
作者
Shi, Zhong-Xing [1 ]
Li, Chang -Fu [2 ]
Zhao, Li-Feng [3 ]
Sun, Zhong-Qi [4 ]
Cui, Li -Ming [1 ]
Xin, Yan-Jie [4 ]
Wang, Dong-Qing [1 ]
Kang, Tan-Rong [1 ]
Jiang, Hui-Jie [4 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Intervent Radiol, Harbin 150086, Peoples R China
[2] Daqing Longnan Hosp, Dept Digest Med, Daqing 163453, Peoples R China
[3] Daqing Longnan Hosp, Dept Radiol, Daqing 163453, Peoples R China
[4] Harbin Med Univ, Affiliated Hosp 2, Dept Radiol, Harbin 150086, Peoples R China
关键词
Hepatocellular carcinoma; Transarterial chemoembolization; Radiomics; Treatment response; Prediction; PROGNOSIS;
D O I
10.1016/j.hbpd.2023.06.011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: According to clinical practice guidelines, transarterial chemoembolization (TACE) is the standard treatment modality for patients with intermediate -stage hepatocellular carcinoma (HCC). Early prediction of treatment response can help patients choose a reasonable treatment plan. This study aimed to investigate the value of the radiomic-clinical model in predicting the efficacy of the first TACE treatment for HCC to prolong patient survival. Methods: A total of 164 patients with HCC who underwent the first TACE from January 2017 to September 2021 were analyzed. The tumor response was assessed by modified response evaluation criteria in solid tumors (mRECIST), and the response of the first TACE to each session and its correlation with overall survival were evaluated. The radiomic signatures associated with the treatment response were identified by the least absolute shrinkage and selection operator (LASSO), and four machine learning models were built with different types of regions of interest (ROIs) (tumor and corresponding tissues) and the model with the best performance was selected. The predictive performance was assessed with receiver operating characteristic (ROC) curves and calibration curves. Results: Of all the models, the random forest (RF) model with peritumor ( + 10 mm) radiomic signatures had the best performance [area under ROC curve (AUC) = 0.964 in the training cohort, AUC = 0.949 in the validation cohort]. The RF model was used to calculate the radiomic score (Rad-score), and the optimal cutoff value (0.34) was calculated according to the Youden's index. Patients were then divided into a high -risk group (Rad-score > 0.34) and a low -risk group (Rad-score <= 0.34), and a nomogram model was successfully established to predict treatment response. The predicted treatment response also allowed for significant discrimination of Kaplan -Meier curves. Multivariate Cox regression identified six independent prognostic factors for overall survival, including male [hazard ratio (HR) = 0.500, 95% confidence interval (CI): 0.260-0.962, P = 0.038], alpha-fetoprotein (HR = 1.003, 95% CI: 1.002-1.004, P < 0.001), alanine aminotransferase (HR = 1.003, 95% CI: 1.0 01-1.0 05, P = 0.025), performance status (HR = 2.400, 95% CI: 1.20 0-4.80 0, P = 0.013), the number of TACE sessions (HR = 0.870, 95% CI: 0.780-0.970, P = 0.012) and Rad-score (HR = 3.480, 95% CI: 1.416-8.552, P = 0.007). Conclusions: The radiomic signatures and clinical factors can be well -used to predict the response of HCC patients to the first TACE and may help identify the patients most likely to benefit from TACE. (c) 2023 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:361 / 369
页数:9
相关论文
共 50 条
  • [21] Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study
    Lu, Linbin
    Zheng, Peichan
    Wu, Zhixian
    Chen, Xiong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma
    Liu, Guanghua
    Ouyang, Qiang
    Xia, Fang
    Fan, Guoping
    Yu, Juming
    Zhang, Caiyuan
    Wang, Dengbin
    HPB, 2019, 21 (01) : 107 - 113
  • [23] Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases
    Izumoto, Hirofumi
    Hiraoka, Atsushi
    Ishimaru, Yoshihiro
    Murakami, Tadashi
    Kitahata, Shogo
    Ueki, Hidetaro
    Aibiki, Toshihiko
    Okudaira, Tomonari
    Miyamoto, Yuji
    Yamago, Hiroka
    Iwasaki, Ryuichiro
    Tomida, Hideomi
    Mori, Kenichiro
    Kishida, Masato
    Tsubouchi, Eiji
    Miyata, Hideki
    Ninomiya, Tomoyuki
    Kawasaki, Hideki
    Hirooka, Masashi
    Matsuura, Bunzo
    Abe, Masanori
    Hiasa, Yoichi
    Michitaka, Kojiro
    Kudo, Masatoshi
    ONCOLOGY, 2017, 93 : 120 - 126
  • [24] Radiologic Patterns Determine the Outcomes of Initial and Subsequent Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
    Hung, Ya-Wen
    Lee, I-Cheng
    Chi, Chen-Ta
    Lee, Rheun-Chuan
    Liu, Chien-An
    Chiu, Nai-Chi
    Hwang, Hsuen-En
    Chao, Yee
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    LIVER CANCER, 2024, 13 (01) : 29 - 40
  • [25] Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
    Hatanaka, Takeshi
    Yata, Yutaka
    Naganuma, Atsushi
    Kakizaki, Satoru
    CANCERS, 2023, 15 (06)
  • [26] Post progression survival in patients with intermediate-stage hepatocellular carcinoma after receiving transarterial chemoembolization
    Shima, Yukiko
    Ogasawara, Sadahisa
    Ooka, Yoshihiko
    Kobayashi, Kazufumi
    Maruta, Susumu
    Kanzaki, Hiroaki
    Kanayama, Kengo
    Maeda, Takahiro
    Kusakabe, Yuko
    Kiyono, Soichiro
    Nakamura, Masato
    Saito, Tomoko
    Suzuki, Eiichiro
    Nakamoto, Shingo
    Yasui, Shin
    Tawada, Akinobu
    Chiba, Tetsuhiro
    Arai, Makoto
    Kanda, Tatsuo
    Maruyama, Hitoshi
    Kato, Naoya
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E75 - E75
  • [27] Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma
    Chen, Mingyu
    Cao, Jiasheng
    Hu, Jiahao
    Topatana, Win
    Li, Shijie
    Juengpanich, Sarun
    Lin, Jian
    Tong, Chenhao
    Shen, Jiliang
    Zhang, Bin
    Wu, Jennifer
    Pocha, Christine
    Kudo, Masatoshi
    Amedei, Amedeo
    Trevisani, Franco
    Sung, Pil Soo
    Zaydfudim, Victor M.
    Kanda, Tatsuo
    Cai, Xiujun
    LIVER CANCER, 2021, 10 (01) : 38 - 51
  • [28] Radiomics features of computed tomography and magnetic resonance imaging for predicting response to transarterial chemoembolization in hepatocellular carcinoma: a meta-analysis
    Feng, Lijuan
    Chen, Qianjuan
    Huang, Linjie
    Long, Liling
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study
    Zheng, Yitao
    Xiang, Yanjun
    Shi, Hongqi
    Lin, Zhuoqun
    Cheng, Shuqun
    Zhu, Jiuting
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1079 - 1093
  • [30] Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study
    Dan-Dan Wang
    Jin-Feng Zhang
    Lin-Han Zhang
    Meng Niu
    Hui-Jie Jiang
    Fu-Cang Jia
    Shi-Ting Feng
    Hepatobiliary & Pancreatic Diseases International, 2023, 22 (06) : 594 - 604